Humana (NYSE:HUM) Issues FY 2026 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 9.000-9.000 for the period, compared to the consensus EPS estimate of 12.030. The company issued revenue guidance of -.

Humana Trading Up 1.9%

Shares of NYSE HUM traded up $3.28 during midday trading on Thursday, reaching $178.68. The company had a trading volume of 1,279,920 shares, compared to its average volume of 2,342,533. The stock has a market cap of $21.49 billion, a PE ratio of 16.73, a price-to-earnings-growth ratio of 1.50 and a beta of 0.44. Humana has a one year low of $169.61 and a one year high of $315.35. The firm’s fifty day moving average price is $247.61 and its 200-day moving average price is $261.75. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.01) by $0.05. The business had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. Humana had a return on equity of 12.86% and a net margin of 1.02%.Humana’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period last year, the company earned ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, equities research analysts anticipate that Humana will post 16.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. KeyCorp reiterated a “sector weight” rating on shares of Humana in a report on Friday, December 12th. Evercore ISI lowered their price objective on shares of Humana from $260.00 to $180.00 in a research note on Thursday. Leerink Partners cut their target price on Humana from $267.00 to $185.00 and set a “market perform” rating on the stock in a research note on Thursday. Robert W. Baird reduced their price target on Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a report on Thursday, December 11th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Humana in a report on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $252.05.

More Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Q4 beat on revenue and slight EPS outperformance: Humana reported revenue of $32.64B (up 11% Y/Y) and an EPS loss slightly better than consensus, helped by CenterWell unit strength — evidence the underlying business still has revenue momentum. MarketBeat Q4 Release
• Positive Sentiment: Membership growth opportunity: Management outlined ~25% Medicare Advantage membership growth for 2026 and said Humana could become the largest MA insurer — a potential long‑term revenue lever if margins recover. Seeking Alpha: Membership Growth
• Neutral Sentiment: Operational commentary cautious: The earnings call struck a cautious tone — management is prioritizing margin recovery even as it scales MA membership, so near‑term guidance and execution will be the focus. TipRanks: Earnings Call Highlights
• Neutral Sentiment: Non‑core real estate note: Humana’s downtown building redevelopment into a hotel is a non‑operational item investors may watch but it’s unlikely to move the stock materially near term. Lane Report: Building Redevelopment
• Negative Sentiment: Guidance well below expectations: Humana set FY2026 EPS guidance at $9.00 vs. street estimates ~12.03, citing lower MA quality (Star) ratings and higher medical costs — the primary driver of recent negative sentiment. Reuters: Guidance Below Estimates
• Negative Sentiment: Analysts cut price targets / maintain cautious ratings: Several firms sharply lowered targets (Evercore to $180, Cantor Fitzgerald to $201, Leerink to $185) reflecting the weaker outlook and Star Ratings risk — increasing downside pressure as sell‑side expectations reset. MarketScreener: Evercore MarketScreener: Cantor MarketScreener: Leerink
• Negative Sentiment: Profit and margin pressure: Q4 GAAP loss widened and the company cited surging medical costs and Star Ratings headwinds; several outlets note Humana hit a 52‑week low after the outlook. Forbes: Wider Loss

Hedge Funds Weigh In On Humana

Large investors have recently made changes to their positions in the business. New York State Common Retirement Fund lifted its stake in Humana by 16.2% during the 4th quarter. New York State Common Retirement Fund now owns 128,735 shares of the insurance provider’s stock valued at $32,973,000 after acquiring an additional 17,902 shares during the period. Brown Brothers Harriman & Co. raised its holdings in shares of Humana by 24.9% during the fourth quarter. Brown Brothers Harriman & Co. now owns 2,145 shares of the insurance provider’s stock valued at $549,000 after purchasing an additional 427 shares during the last quarter. McMillan Office Inc. bought a new position in Humana during the fourth quarter valued at approximately $1,234,000. denkapparat Operations GmbH purchased a new stake in Humana in the fourth quarter worth approximately $429,000. Finally, South Dakota Investment Council grew its position in Humana by 8.4% in the 4th quarter. South Dakota Investment Council now owns 161,383 shares of the insurance provider’s stock worth $41,335,000 after purchasing an additional 12,541 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.